KR930023370A - 단백질 씨(c) 유도체 - Google Patents

단백질 씨(c) 유도체 Download PDF

Info

Publication number
KR930023370A
KR930023370A KR1019930008613A KR930008613A KR930023370A KR 930023370 A KR930023370 A KR 930023370A KR 1019930008613 A KR1019930008613 A KR 1019930008613A KR 930008613 A KR930008613 A KR 930008613A KR 930023370 A KR930023370 A KR 930023370A
Authority
KR
South Korea
Prior art keywords
derivatives
human protein
flin
protein
protein seed
Prior art date
Application number
KR1019930008613A
Other languages
English (en)
Other versions
KR100291529B1 (ko
Inventor
에드워드 게르리츠 브루스
윌리엄 그린 넬 브라이언
Original Assignee
리로이 휘테커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리로이 휘테커, 일라이 릴리 앤드 캄파니 filed Critical 리로이 휘테커
Publication of KR930023370A publication Critical patent/KR930023370A/ko
Application granted granted Critical
Publication of KR100291529B1 publication Critical patent/KR100291529B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

높은 활성 및 트롬빈 활성화에 대한 감소된 의존성을 지닌 인간 단백질 C 유도체들이 기술되어 있다. 상기 유도체들은 그들의 증가된 활성화율, 기능적 활성 및 탄수화물 구조에 있어서 천연형태의 인간 단백질 C와는 다르다. 상기 유도체들을 생산하는데 유용한 DNA 화합물, 이전 벡터, 발현 벡터 및 형질전환체들이 또한 기술되어 있다.

Description

단백질 씨(C)유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. Q3Q9, FLIN-Q313 및 FLIN-Q3Q9으로 이루어진 그룹으로부터 선택된 인간 단백질 C 유도체.
  2. 제 1항의 인간 단백질 C유도체를 암호화하는 재조합 DNA 분자.
  3. 활성 성분으로서 Q3Q9, FLIN-Q313 및 FLIN-Q3Q9으로 이루어진 그룹으로 부터 선택된 단백질 C 유도체를 하나이상의 약제학적으로 허용되는 담체, 부형제 또는 희석제와 함께 포함하는 항혈전 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930008613A 1992-05-21 1993-05-19 단백질 씨 유도체 KR100291529B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21
US887,191 1992-05-21

Publications (2)

Publication Number Publication Date
KR930023370A true KR930023370A (ko) 1993-12-18
KR100291529B1 KR100291529B1 (ko) 2001-06-01

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930008613A KR100291529B1 (ko) 1992-05-21 1993-05-19 단백질 씨 유도체

Country Status (23)

Country Link
US (1) US5453373A (ko)
EP (1) EP0575054B1 (ko)
JP (1) JP3564150B2 (ko)
KR (1) KR100291529B1 (ko)
CN (1) CN1080658A (ko)
AT (1) ATE286121T1 (ko)
AU (1) AU661901B2 (ko)
BR (1) BR9301944A (ko)
CA (1) CA2096604C (ko)
CZ (1) CZ286016B6 (ko)
DE (1) DE69333727T2 (ko)
DK (1) DK0575054T3 (ko)
ES (1) ES2233925T3 (ko)
FI (1) FI932282A (ko)
HU (1) HU218408B (ko)
IL (1) IL105757A0 (ko)
MX (1) MX9302917A (ko)
MY (1) MY110664A (ko)
NO (1) NO311299B1 (ko)
NZ (1) NZ247651A (ko)
PH (1) PH29911A (ko)
PT (1) PT575054E (ko)
RU (1) RU2122004C1 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
WO1993007491A1 (en) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
BR9809304B1 (pt) 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CA2293429A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
AU5131699A (en) * 1998-07-31 2000-02-21 Eli Lilly And Company Cryogranulation of activated protein c
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
IL142248A0 (en) 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
IL142255A0 (en) 1998-11-13 2002-03-10 Lilly Co Eli Method of treating heparin-induced thrombocytopenia
ES2195655T3 (es) 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
WO2001036462A2 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CN100392079C (zh) * 2000-10-18 2008-06-04 马克西根公司 蛋白c或活化的蛋白c-样分子
KR20030060915A (ko) * 2000-10-18 2003-07-16 맥시겐 에이피에스 단백질 씨 또는 활성 단백질 씨-유사 분자
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
WO2003106666A2 (en) * 2002-06-14 2003-12-24 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1773371A4 (en) * 2004-07-23 2009-12-30 Univ Rochester ACTIVATED PROTEIN C INHIBITS SIDE EFFECTS OF PLASMINOGEN ACTIVATOR IN THE BRAIN
WO2006136033A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
US20100184672A1 (en) * 2007-06-18 2010-07-22 Mccarty Owen J T Protein c for use in maintaining hemostasis
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN102325880B (zh) 2008-12-19 2014-10-01 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
HU9301461D0 (en) 1993-09-28
AU3869993A (en) 1993-11-25
NO931840L (no) 1993-11-22
US5453373A (en) 1995-09-26
EP0575054A2 (en) 1993-12-22
EP0575054B1 (en) 2004-12-29
NO931840D0 (no) 1993-05-19
CA2096604C (en) 2003-12-16
IL105757A0 (en) 1993-09-22
NO311299B1 (no) 2001-11-12
KR100291529B1 (ko) 2001-06-01
CZ94893A3 (en) 1994-01-19
CN1080658A (zh) 1994-01-12
DE69333727D1 (de) 2005-02-03
HU218408B (hu) 2000-08-28
FI932282A (fi) 1993-11-22
CZ286016B6 (cs) 1999-12-15
AU661901B2 (en) 1995-08-10
MX9302917A (es) 1993-11-01
JPH0680698A (ja) 1994-03-22
JP3564150B2 (ja) 2004-09-08
NZ247651A (en) 1995-03-28
ES2233925T3 (es) 2005-06-16
PT575054E (pt) 2005-03-31
HUT69615A (en) 1995-09-28
DE69333727T2 (de) 2005-12-15
PH29911A (en) 1996-09-16
ATE286121T1 (de) 2005-01-15
DK0575054T3 (da) 2005-04-25
RU2122004C1 (ru) 1998-11-20
FI932282A0 (fi) 1993-05-19
CA2096604A1 (en) 1993-11-22
BR9301944A (pt) 1993-11-30
MY110664A (en) 1999-01-30
EP0575054A3 (en) 1995-04-19

Similar Documents

Publication Publication Date Title
KR930023370A (ko) 단백질 씨(c) 유도체
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
DK1288223T3 (da) Terapeutiske peptidderivater
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
ATE184009T1 (de) Halichondrine: zytotoxische polyäther-makrolide
ES2110009T3 (es) Derivados de la estreptolisina o.
ES2099274T3 (es) Derivados de estreptolisina o.
ATE90359T1 (de) Peptide.
ATE175213T1 (de) Ch0ndromodulin-ii protein
KR910000645A (ko) 개선된 경련치료제
ES2129022T3 (es) Proteina condromodulina-i.
ATE174911T1 (de) 1-dimethylcarbamoyl-1h-1,2,4-triazole- substituiert in stellungen 3 und 5
YU34793A (sh) Derivati proteina c
IT8622051A1 (it) Composizioni farmaceutiche ad attivita' cicatrizzante

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee